Risk Factors for Hepatic Toxicity of High-dose Methotrexate in Patients With Osteosarcoma

Kentaro Abe, Ayako Maeda-Minami, Taku Ishizu, Shintaro Iwata, Eisuke Kobayashi, Tatsunori Shimoi, Yohei Kawano, Hironobu Hashimoto, Masakazu Yamaguchi, Tetsuya Furukawa, Satoru Miyazaki, Yasunari Mano

Research output: Contribution to journalArticlepeer-review


Background/Aim: High-dose methotrexate (HD-MTX) is widely used to treat osteosarcoma. However, some patients develop hepatic toxicity, leading to dose modification and delays in the scheduled chemotherapy. The present study aimed to identify the risk factors of hepatotoxicity in patients with osteosarcoma. Patients and Methods: We conducted a retrospective study of patients with osteosarcoma treated with HD-MTX between January 2014 and June 2020 at the National Cancer Center Hospital, Japan. The risk factors for MTX-induced hepatotoxicity (≥grade 3) were identified using multivariate logistic regression analysis. Results: The final analysis included 88 courses of 36 patients. Hepatotoxicity occurred in 51 (58.0%) of the 88 courses. Female sex, MTX dose (>10.2 g/m2), and serum calcium concentration (>9.3 mg/dl) were identified as risk factors for HD-MTX-induced hepatotoxicity. Conclusion: Identifying the risk factors of HD-MTX-induced hepatotoxicity may contribute to improvements in the safety and management of HD-MTX therapy.

Original languageEnglish
Pages (from-to)1043-1050
Number of pages8
JournalAnticancer research
Issue number2
Publication statusPublished - Feb 2022


  • Clinical study
  • Hepatic dysfunction
  • High-dose methotrexate (HD-MTX)
  • Osteosarcoma


Dive into the research topics of 'Risk Factors for Hepatic Toxicity of High-dose Methotrexate in Patients With Osteosarcoma'. Together they form a unique fingerprint.

Cite this